TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group.
Iezzi R, et al.
Eur Radiol. 2019 Mar;29(3):1285-1292. doi: 10.1007/s00330-018-5692-8. Epub 2018 Aug 31.
Eur Radiol. 2019.
PMID: 30171360